Tuesday, June 9, 2009 Walter E. Washington Convention Center Room 152A Program Director: Susan J. Mandel, MD, MPH - Univ of Pennsylvania Sch of Med
Advanced Thyroid Ultrasound Workshop | 9:45 AM – 2:15 PM
CME Credits: 4.5 hours This course is designed to introduce participants to
the use of ultrasound for examination of the cervical lymph nodes and
parathyroid adenomas. There will be 4 lectures and one hands-on session
with participation by patients with thyroid cancer and
hyperparathyroidism.
Objectives: As a result of participating in this educational activity, learners will be able to: (1) Review indications for ultrasound examination of cervical lymph nodes in thyroid cancer patients; (2) Demonstrate the imaging procedure and characteristics of benign and malignant lymph nodes; (3) Discuss and illustrate the imaging characteristics of parathyroid adenomas; and (4) Practice slide preparation and cytology specimen interpretation.
Program Overview: 9:45 - 9:50 AM Welcome & Introduction
9:50 - 10:15 AM Metastatic Lymph Nodes: Why They Matter Richard T. Kloos, MD - Ohio State Univ
10:15 - 10:45 AM The use of Sonography for Detection of Metastatic Lymph Nodes in Cancer Susan J. Mandel, MD, MPH - Univ of Pennsylvania Sch of Med
10:45 - 11:15 AM Diagnostic Ultrasound of Parathyroid Glands Stephanie A. Fish, MD - Univ of Pennsylvania Sch of Med
11:15 - 11:45 AM Thyroid Cytology Adequacy Nicole A. Massoll, MD - Univ of Florida
11:45 AM - 12:15 PM Q&A Session
12:15 - 2:15 PM PRACTICUM: DIAGNOSTIC THYROID ULTRASOUND Registration Prerequisite: The
registrant must currently be performing diagnostic thyroid ultrasound
and ultrasound-guided fine-needle aspiration biopsies routinely in
his/her practice. Registration Fees: Member: $395 Non Member: $455 In Training: $275
CME Credits: 4.75 hours This 5-hour course is designed to introduce participants to the use of ultrasound in the diagnosis of thyroid nodules and perform ultrasound-guided fine-needle aspirations. There will be 4 lectures and one hands-on session.
Objectives: As a result of participating in this educational activity, learners will be able to: (1) Review the technology of ultrasound imaging; (2) Demonstrate the imaging characteristics of thyroid nodules and diffuse thyroid disorders; (3) Perform diagnostic thyroid ultrasound imaging and identify normal neck anatomy; (4) Perform ultrasound-guided fine-needle aspiration biopsies using a simulated model; and (5) Practice slide preparation and cytology specimen interpretation.
Program Overview: 1:30 - 1:35 PM Welcome & Introduction
1:35 - 2:00 PM Concepts of Ultrasound Physics and Instrumentation Stephanie A. Fish, MD - Univ of Pennsylvania Sch of Med
2:00 - 2:45 PM Thyroid Ultrasound: Diagnostic Use Susan J. Mandel, MD, MPH - Univ of Pennsylvania Sch of Med
2:45 - 3:00 PM Break
3:00 - 3:25 PM Ultrasound of Diffuse Thyroid Disorders Erik K. Alexander, MD - Brigham & Women's Hosp
3:25 - 3:45 PM Ultrasound-Guided Fine-Needle Aspiration Bryan R. Haugen, MD - Univ of Colorado Health Sci Ctr
Registration Fees: Member: $365 Non Member: $425 In Training: $250
REGISTER FOR THIS EVENT: Registration for these courses is now closed.
The 2nd Endocrine Society Forum on Endocrine Disruptors: Best Science for Risk Management and Policy
Co-sponsored by the American Thyroid Association, the Society for Toxicology and the Society for the Study of Reproduction Jun 9, 2009 | 7:00 a.m. to 5:00 PM
Walter E. Washington Convention Center Room 147A-B CME Credits: 8 hours
Organizing Committee: R. Thomas Zoeller, PhD, Univ. Mass. Amherst, Andrea C. Gore, PhD, Univ. Texas Austin, Alan L. Schneyer, PhD, Pioneer Valley Life Sciences Institute
Held the day before ENDO 09 in Washington, D.C., this forum will inform Society members about the basic and clinical science of endocrine disrupting chemicals (EDCs), and will bring cutting-edge endocrinology to regulators and policymakers.Endocrine research is lacking in recent well-publicized risk assessments for EDCs such as bisphenol-A, phthalates, and perchlorate, which rely heavily on toxicological studies. Understanding the mechanisms by which EDCs alter endocrine function in child development or adult physiology is important to public health and health policy. In addition, it is critical to quantify the risk of EDC exposure to the human population. Endocrinologists are well versed in the methods required to understand the mechanism of action of chemicals that act on development and physiology.Endocrine research is critically needed to provide adequate information for effective risk assessment and development of regulations in order to inform a public health agenda.
Program Overview: 7:00 - 8:00 AM Registration
8:00 - 8:10 AM Welcome R. Thomas Zoeller, PhD, Univ Mass-Amherst, Workshop Chair
8:10 - 8:30 AM Introductory Remarks Robert M. Carey, MD, President, The Endocrine Society and Alan L. Schneyer, PhD, Basic Research Subcommittee Chair, The Endocrine Society's Research Affairs Core Committee
8:30 - 9:00 AM Keynote Address and Discussion: Government and Public Health Protection Jerrold Heindel, PhD, National Inst of Environmental Hlth Sci
9:00 – 10:30 AM ENDOCRINE DISRUPTORS AND PUBLIC HEALTH PROTECTION Andrea C. Gore, PhD, Univ of Texas-Austin, Moderator
Population Risk Versus Individual Risk--Endocrine Disruptors in the Public Health Arena Bruce P. Lanphear, MD, MPH , Simon Fraser Univ, Canada
The Endocrine Disruptor Screening Program: History and Challenges for the Future Leslie W. Touart, PhD, U.S. EPA
Discussion Moderated by Dr. Gore 10:30 – 10:45 AM Coffee Break
10:45 AM – 12:15 PM THE BASIC BIOLOGY OF ENDOCRINE DISRUPTORS Ana M. Soto, PhD, Tufts Univ, Moderator
Environmental Estrogens: Integrating Toxicology and Endocrinology Cheryl L. Walker, PhD, Univ of Texas, MD Anderson Cancer Ctr
Environmental Androgens: Integrating Toxicology and Endocrinology Kevin W. Gaido, PhD, Hamner Inst for Health Sci
Environmental Thyroid Disruptors: Integrating Toxciology and Endocrinology Josef Köhrle, PhD, Charite Hosp, Berlin
Discussion Moderated by Dr. Soto
12:15 - 1:30 PM Lunch (Directed Discussion)
1:30 - 3:00 PM ENDOCRINE DISRUPTORS IN THE HUMAN POPULATION Deborah A. Cory-Slechta, PhD, Univ of Rochester, Moderator
Bisphenol A Exposure and Public Health Tamara Galloway, PhD, Univ of Exeter, UK
Endocrine Disruptors and the Testicular Dysgenesis Syndrome Niels E. Skakkebaek, MD, PhD, Univ Copenhagen, Denmark
Perchlorate and Public Health Craig Steinmaus, MD, PhD, California EPA
Discussion Moderated by Dr. Cory-Slechta
3:00 – 3:30 PM Break
3:30 – 4:00 PM DATA GAPS IMPORTANT FOR THE REGULATORY APPARATUS Elaine Z. Francis, PhD, U.S. EPA
4:00 – 5:00 PM Round-Table Discussion*
*Panel members include Deborah Cory-Slechta, Jerrold Heindel, and Elaine Francis.The moderated discussion will focus on the most effective means of bringing sound endocrine research to bear on EDC policy.Designated Forum Discussants: Frederick S. von Saal, PhD, Univ Missouri and John Peterson Myers, PhD, Environmental Hlth Sci.
REGISTER FOR THIS EVENT:To register for this workshop only (without attending ENDO),
please fill out the ENDO 09 registration form (you may need to disable Pop-up Blocker) and fax it to the number on
the form.If you wish to attend the Forum and ENDO 09, please visithttp://registration.experient-inc.com/showEND091/Default.aspx . If you have already registered for ENDO 09 and would like to add the Forum to your registration, you may login online and add the event or call the ENDO 09 Registrar at 866.229.2386 (US toll free) or 301.694.5243. For more information, contact Loretta Doan, PhD, Associate Director, Science Policy, atldoan@endo-society.org or 301-941-0258.
Medical Science Liaison Endocrinology Workshop
Tuesday, June 9, 2009 | 2:00 - 6:30 PM Walter E. Washington Convention Center Room 152B CME Credits: 3.5 hours
The Society has created this special pre-ENDO workshop specifically designed for Medical Science Liaisons with a focus in endocrinology. Join your peers at a workshop designed for you that will feature a Keynote Session on the State of Endocrinology and Scientific Overviews on three therapeutic areas – cardiovascular endocrinology, diabetes & obesity, and bone & mineral presented by recognized leaders in each area.The meeting will conclude with a special networking session so you can meet and network with other MSL professionals.
Objectives:
Upon completion of this educational activity, learners will be able to: (1) Facilitate discussion of current and future advances in endocrinology; and (2) Translate the latest updates in the areas of cardiovascular endocrinology, diabetes & obesity, and bone & mineral to clinical applications.
Program Overview:
2:00 – 2:10PM Welcome
2:10 – 3:00PM Keynote Session: State of Endocrinology Andrea E. Dunaif, MD - Northwestern Univ Med Sch
3:00 – 3:45PM Scientific Overview – Cardiovascular Endocrinology James R. Sowers, MD - Univ of Missouri
3:45 – 4:00PM Break
4:00 – 4:45PM Scientific Overview – Diabetes & Obesity Anthony McCall, MD, PhD - Univ of Virginia Health Syst
4:45 – 5:30PM Scientific Overview – Bone & Mineral John Bilezikian, MD - Columbia Univ Coll of Phys & Surg
Friday, June 12 | 6:30 - 9:30 pm Grand Hyatt Washington Hotel
1000 H. Street NW, Washington, DC
Constitution Ballroom
CME Credits: 2.5 hours
Program Director: Jason A. Wexler, MD - Washington Hosp Ctr
Join The Endocrine Society's first Practice Management Workshop created to assist endocrinologists in deciphering the complex world of practice management. This three-hour event will provide you with an opportunity to learn about and discuss accurate and current information on practice management topics.
Objectives: Upon completion of this activity, participants will be able to: (1) Select appropriate codes to maximize reimbursement; (2) Describe the benefits of EMRs in office management; and (3) Identify and manage risk in an endocrine practice.
Program Overview: 6:30 – 7:00 PM Registration & Meal Service
7:00 – 7:05 PM Welcome & Introduction Jason A. Wexler, MD - Washington Hospital Ctr
7:05 – 7:40 PM Coding for Maximum Reimbursement Reinhard W. Beel, CEC, CDT - Cumberland Valley Endocrinology Ctr
7:40 – 8:15 PM Electronic Medical Record Systems (EMRs) for Endocrinologists Claudia Tessier, RHIA - mHealth Initiative
8:15 – 8:50 PM Risk Management in an Endocrine Practice Nancy R. Smit, MBA, RPT, RRT - SHR Associates, Inc.
8:50 – 9:30 PM Q&A Session
Registration Fees: Members: $125 Non-Members: $150 Nurses/office staff: $75 Member Physician and office staff (price for two): $150
Wednesday, June 10, 2009 | 6:30 – 10:00 PM Renaissance Washington DC Hotel
999 Ninth Street NW, Washington DC Renaissance Ballroom CME Credits: 1.5 hours
We are fortunate to have Vivian Pinn, MD, Director of the Office of Research on Women's Health at the National Institutes of Health as our keynote speaker. The title of her talk will be Sustaining Women Leaders in Science and Medicine: Progress and Pitfalls.
For more information, visit the Women in Endocrinology Web siteor for special dietary requests, please contact Mary Ruppe, MD at (713) 500-6901 or mary.ruppe@uth.tmc.edu. Sign up for this event when you register to attend ENDO. Advance registration and fee required.
National Institute of Health Exhibit at ENDO 09
The National Institutes of Health (NIH) and The Endocrine Society are connecting with basic and clinical researchers through interactive discussions and networking opportunities at ENDO with an expanded exhibit presence. In addition to visiting the enlarged exhibit area, you should plan to attend one of several informative presentations in the ENDO Exhibit Theater. These presentations provide a forum for researchers to learn about new programs and services at various NIH institutes. ENDO is the ideal venue to engage with several institutes including NIDDK, NICHD, NIA, NIEHS, NINDS, NHLBI, and NCCAM to name a few. Join your colleagues in advancing the science of endocrinology. Share, connect and engage at ENDO.
There are two ways to compete. As an indivdual or in a team.
Individual: Come by the ENDO booth at the Annual Meeting to pick up your free pedometer. Track the number of steps you walk while at the meeting and compete for a grand prize. By registering you’re also eligible to win a prize in a daily raffle.
Team Challenge: New this year, the team challenge is open to academic institutions, trainees, corporations, and other organizations. There is no fee to register and each team is limited to 10 participants. For more information about how to register your team click here or contact Anna Meenan at (301) 951-2619 or ameenan@endo-society.org.
To learn more about The Hormone Foundation, the public education affiliate of The Endocrine Society, visit www.hormone.org
The
2009 Step Challenge is supported by: Takeda Pharmaceuticals North America Inc.,
Abbott Laboratories, Bristol-Myers Squibb, Genentech, and Wyeth Pharmaceuticals.
7th Annual Meeting of Androgen Excess & PCOS Society
Tuesday, June 9, 2009 | 8:00AM– 5:00 PM Embassy Suites DC Convention Center Hotel 900 10th Street NW Washington, DC 20001
The meeting will focus on recent developments in pathophysiology and treatment of Polycystic Ovary Syndrome (PCOS) and other androgen excess disorders.
Registration fee is $150 for members of AEPCOS Society ($100 before April 3, 2009) and $200 for non members. The registration fee includes admission to the scientific sessions, certificate of attendance, abstract book, meeting material, badge, two coffee breaks and a light lunch.
Tuesday, June 9, 2009, | 8:00AM– 6:00 PM RenaissanceWashingtonDCHotel 999 Ninth Street NW, Washington, DC 20001 Program Chair: Richard J. Auchus, MD, PhD - Univ of Texas Southwestern Med Ctr
This meeting is jointly sponsored by CARES Foundation and The University of Texas Southwestern Medical Center, the accredited sponsor. This workshop will focus on adrenal disorders with an emphasis on Congenital Adrenal Hyperplasia throughout the lifespan.The University of Texas Southwestern Medical Center designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credits™.Physicians should only claim credit commensurate with the extent of their participation in the activity.
Program topics include: Adrenal Development and Related Disorders; CAH Pregnancy, Newborn Screening, Neonate and Infant; CAH: The Child and Adolescent; CAH: Transition to Adulthood and Adult Life; Non-Clasic CAH; CAH other than 21-Hydroxylase Deficiency; Cushing's Disease Diagnosis and Evaluation; and Adrenal HTN: Primary Adlosteronism & Pheochormocytoma.
11th Annual Pituitary Congress June 13-15, 2009 Omni Shoreham Hotel 2500 Calvert Street NW Washington, DC 20008
The Pituitary Society presents the 11th International Pituitary Congress, June 13-15, immediately following ENDO. This year'scutting edge scientific presentations will highlight growth hormone, including a session devoted to pediatric neuroendocrinology in addition to sessionsfocused oncardiovascular disease, competitive sports, body composition, genetic syndromes, pituitary tumor biology and other pituitary physiology and diseases.
Continuing the tradition of our past Congresses the 11th International Congress promisses to provide attendees with excellent science, clinical applications and exciting social events. The meeting will be held at the Omni Shoreham Hotel.
Thursday, June 11, 2009, | 6:30– 8:30 PM Grand Hyatt Hotel 1000 H Street NW, Washington, DC 20001 Supported by Merck & Co., Inc.
The Minority Affairs Committee is hosting this reception during ENDO,where advisors at topic tables are available to address career challenges facing minority students, postdocs, fellows and faculty. Minority trainees interested in presenting their research are also invited to attend. This event presents a great networking opportunity for mentors from The Endocrine Society, industry, and government to share their career experiences and advice for young scientists. You can register to become a mentor in spring 2009.
Continuing Medical Education Services (CMES) Ancillary Symposia
These ancillary symposia were developed through The Endocrine Society's Continuing Medical Education Services (CMES). They will be held at either the Grand Hyatt Washington or Renaissance Washington DC hotels, before or after the ENDO 09 plenary sessions.
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society’s Special Program Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.
All ancillary symposia are CME accredited by The Society, and planned and conducted in strict compliance with the Essential Standards & Guidelines of the Accreditation Council for Continuing Medical Education (ACCME). Symposia are subject to change.
There is no cost to attend the CMES Ancillary Symposia. However, SEATING IS LIMITED FOR THESE EVENTS; therefore reservation tickets will be made available via the ENDO 09 Registration System. Reservation tickets are valid for 15 minutes after the advertised opening times listed below. After 15 minutes, seating will be made available to all attendees on a first-come, first-served basis.
TO REGISTER FOR ANY OF THESE ACTIVITIES:Please be aware that registration for these sessions is limited; to register online, please visit http://registration.experient-inc.com/showEND091/Default.aspxor fill out the ENDO CMES registration form and fax it to the number listed on the form (courses no longer accepting pre-registration are indicated on this form).
Continuous Glucose Monitoring: State-of-the-Art and Clinical Practice
This educational activity is co-sponsored by The Endocrine Society and the Juvenile Diabetes Research Foundation.
Wednesday, June 10 | 6:00 AM to 8:00 AM Grand Hyatt Washington Hotel 1000 H. Street NW, Washington, DC Constitution Ballroom CME Credits: 1.5 hours Supported by an educational grant from Medtronic Diabetes/LifeScan Alliance and Lilly USA, LLC.
Program Director: Henry Rodriguez, MD - Indiana Univ Sch of Med
Objectives: Upon completion
of this activity, participants will be able to: (1) Explain the
indications and limitations of continuous glucose monitors available at
the present time; (2) Contrast the features of existing continuous
glucose monitoring devices available; (3) Utilize continuous
glucose monitoring data to make clinical decisions; and (4) Teach patients how to make the best use of their CGMs to achieve tight glycemic control. Program Overview: 6:00 – 6:30 AM Registration & Meal Service
6:30 – 6:45 AM Welcome & Introduction Henry Rodriguez, MD - Indiana Univ Sch of Med
6:45 – 7:05 AM Current State of the Art and Latest Results from the JDRF CGM Study Lori M. Laffel, MD, MPH - Joslin Diabetes Ctr
7:05 – 7:25 AM Implementation of CGM in Practice: Case Studies Stuart A. Weinzimer, MD - Yale Univ Sch of Med
7:25 – 7:45 AM Incorporating Continuous Glucose Monitoring in a Healthcare Practice Dan Mendelson - Avalere Health, LLC
2009 CLB Forum: Biomarkers in Cardiovascular Endocrinology in Clinical Trials & Drug Development
Wednesday, June 10, 2009 | 6:30 – 9:30 PM Renaissance Washington DC Hotel 999 Ninth Street NW, Washington DC Grand Ballroom CME Credits: 2.5 hours Supported by The Endocrine Society Corporate Liaison Board Program Director: S. Sethu K. Reddy, MD, MBA - Merck & Co.
Objectives: Upon
completion of this activity, participants will be able to: (1) Explain
the rationale for the identification, development, and application of
biomarkers; (2) Review the current state of biomarkers for
atherosclerosis; (3) Discuss the need for biomarkers for
atherosclerosis as predictors of clinical events; (4) List the most
frequently used novel risk markers for cardiovascular disease; (5)
Describe differences between Lp-PLA2 and other inflammatory biomarkers
like C-reactive protein; (6) Discuss the possible atherosclerotic
mechanism of action of Lp-PLA2; (7) Summarize primary and secondary CV
prevention studies which have demonstrated associations between
elevated Lp-PLA2, cardiovascular events, and stroke; (8) Describe how
Lp-PLA2 may become a therapeutic target in the future; (9) Recognize
distinction between biomarker and surrogate endpoint; (10) Recognize
different applications of biomarkers throughout different phases of
drug development; and (11) Recognize scenarios wherein a validated
surrogate for previous drug approval may still require clinical
outcomes data. Program Overview: 6:30 -7:00 PM Registration & Meal Service
7:00 - 7:15 PM Welcome & Introduction S. Sethu K. Reddy, MD, MBA - Merck & Co.
7:15 - 7:55 PM The Mandate for Development of Biomarkers of Atherosclerotic Cardiovascular Disease: Future Implications David A. Fryburg, MD - Pfizer, Inc.
7:55 - 8:35 PM Novel Cardiovascular Biomarkers: Experience with Lp-PLA2 Joseph P. McConnell, PhD - Mayo Clinic
8:35 - 9:15 PM Regulatory Perspective Mary H. Parks, MD - FDA
The Impact of GLP-1 Receptor Activation on Diabetes Pathophysiology and Disease Management
Wednesday, June 10th | 6:30 – 9:30 pm Grand Hyatt Washington 1000 H. Street NW, Washington, DC Independence Ballroom A CME Credits: 2.5 hours Supported by an educational grant from Novo Nordisk Inc.
Program Director: David A. D'Alessio, MD – Univ of Cincinnati
Objectives: Upon completion of this activity, participants will be able to: (1) Explain how alpha- and beta-cell dysfunction and dysregulated hepatic glucose production contribute to the pathogenesis of type 2 diabetes; (2) Describe the mechanism of action of GLP-1 in regulating glucose levels; (3) Describe the effect of DPP-4 on incretins; and (4) Select among pharmacologic options for type 2 diabetes based on treatment history and degree of disease progression.
Program Overview: 6:30 - 7:00 PM Registration & Meal Service
7:00 – 7:15 PM Welcome & Introduction David A. D'Alessio, MD – Univ of Cincinnati
7:15 – 7:50 PM Incretin Physiology: Effects On The ß-cell and Beyond Tina Vilsbøll, MD - Gentofte Hosp, Univ of Denmark
7:50 – 8:25 PM The Pharmacology of GLP-1 Signaling: GLP-1 Agonists and DPP-4 Inhibitors Richard E. Pratley, MD - University of Vermont
8:25 – 9:00 PM Integration of Incretin-Based Therapy in Diabetes Management Anastassios G. Pittas, MS, MD - Tufts Med Ctr
9:00 – 9:10 PM Summary and Discussion David A. D'Alessio, MD – Univ of Cincinnati
Management Options for Patients with Acromegaly and Large Pituitary Tumors
Wednesday, June 10th | 6:30 – 9:30 pm Grand Hyatt Washington 1000 H. Street NW, Washington, DC Constitution Ballroom CME Credits: 2.5 hours Supported by an educational grant from Ipsen.
Program Director: Lawrence A. Frohman, MD – Univ of Illinois, Chicago
Objectives: Upon completion of this activity, participants will be able to: (1) Select the appropriate initial treatment for patients with acromegaly and large pituitary tumors; and (2) Apply evidence-based medicine in long-term management for patients whose disease has not been adequately controlled by initial treatment.
Program Overview: 6:30 - 7:00 PM Registration & Meal Service
7:00 - 7:15 PM Welcome & Presentation of the Case Lawrence A. Frohman, MD - Univ of Illinois, Chicago
7:15 - 7:50 PM Surgery Should be the Primary Therapy for a Somatotroph Macroadenoma Causing Acromegaly Mark E. Molitch, MD - Northwestern Univ, Feinberg Med Sch
7:50 - 8:25 PM Medical Treatment Should be the Primary Therapy for a Somatotroph Macroadenoma Causing Acromegaly Annamaria Colao, MD, PhD - Univ of Naples Federico II
8:25 - 8:35 PM Case Follow-Up: Results of the Initial Treatment Lawrence A. Frohman, MD - Univ of Illinois, Chicago
8:35 - 9:10 PM Approach to Patients not Optimally Controlled by Primary Therapy David R. Clemmons, MD - Univ of North Carolina Sch of Med
Thursday, June 11th | 6:00 am – 8:00 am Renaissance Washington DC 999 Ninth Street NW, Washington DC Grand Ballroom CME Credits: 1.5 hours Supported by an educational grant from Solvay Pharmaceuticals, Inc.
Program Director: Bradley D. Anawalt, MD – Univ of Washington
Objectives: Upon completion of this activity, participants will be able to: (1) Better recognize and diagnose male hypogonadism; (2) Associate testosterone deficiency with risks of metabolic syndrome and cardiovascular risk; and (3) Assess the benefits and risks of testosterone replacement in male patients with hypogonadism.
Program Overview: 6:00 - 6:30 AM Registration & Meal Service
6:30 - 6:45 AM Welcome & Introduction Bradley D. Anawalt, MD - Univ of Washington
6:45 - 7:05 AM Difficulties in the Diagnosis of Male Hypogonadism Robert I. McLachlan, MD, PhD - Prince Henry's Inst of Med Res, Australia
7:05 - 7:25 AM Is Testosterone Good for the Heart?
Frances J. Hayes, MB - St. Vincent's Univ Hospital, Ireland
7:25 - 7:45 AM Is Testosterone Bad for the Prostate?
Stephanie T. Page, MD, PhD - Univ of Washington Med Ctr
Multidisciplinary Approach to Management of Neuroendocrine Tumors
Thursday, June 11th | 6:30 pm – 9:30 pm Renaissance Washington DC 999 Ninth Street NW, Washington DC Grand Ballroom CME Credits: 2.5 hours Supported by an educational grant from Novartis Pharmaceuticals Corporation
Program Director: Wouter W. de Herder, MD, PhD - Erasmus Med Ctr
Objectives:
Upon completion of this activity, participants will be able to: (1) Recognize the clinical presentation of neuroendocrine tumors (NETs); (2) Employ the most current imaging technology to facilitate the differential diagnosis and treatment of NETs; and (3) Select the most efficacious treatment options for patients with NETs.
Program Overview: 6:30 - 7:00 PM Registration & Meal Service
7:00 - 7:15 PM Welcome & Introduction
7:15 - 7:45 PM Diagnosis of Neuroendocrine Tumors Anthony P. Heaney, MD, PhD - David Geffen Sch of Med at UCLA
7:45 - 8:15 PM Radiological Imaging of Neuroendocrine Tumors Anju Sahdev, MBBS, MRCP, FRCR - Barts and The London Sch of Med and Dentistry
8:15 - 8:45 PM Therapies for Metastatic Neuroendocrine Tumors Matthew H. Kulke, MD - Dana-Farber Cancer Inst
What's New in Osteoporosis Diagnosis and Treatment
Thursday, June 11th | 6:30 pm – 9:30 pm Grand Hyatt Washington 1000 H. Street NW, Washington, DC Independence Ballroom A CME Credits: 2.5 hours Supported by an educational grant from Amgen.
Program Director: John P. Bilezikian, MD – Columbia Univ Coll of Physicians and Surgeons
Objectives: Upon completion of this activity, participants will be able to: (1) Assess 10 year predicted fracture risk in individual patients using different fracture risk methods, including the FRAX tool; (2) Review the role of the RANK-L system in bone remodeling and as a therapeutic focus for osteoporosis interventions; and (3) Describe future osteoporosis treatments based on molecular targets and pathways leading to osteoblast activation.
Program Overview: 6:30 - 7:00 PM Registration & Meal Service
7:00 - 7:15 PM Welcome & Introduction
7:15 - 7:45 PM The WHO FRAX Model Michael R. McClung, MD – Oregon Osteoporosis Ctr
7:45 - 8:15 PM RANK Ligand as a Target for Intervention in the Treatment of Osteoporosis E. Michael Lewiecki, MD – New Mexico Clinical Res and Osteoporosis Ctr
8:15 - 8:45 PM Future Concepts in Therapeutics for Osteoporosis John P. Bilezikian, MD – Columbia Univ Coll of Physicians and Surgeons
Cases in Practice: Emerging Therapeutic Options and Beyond in the Treatment of Patients with Type 2 Diabetes
Friday, June 12th | 6:00 am – 8:00 am Grand Hyatt Washington 1000 H. Street NW, Washington, DC Independence Ballroom A CME Credits: 1.5 hours Supported by an educational grant from Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.
Program Director: Robert R. Henry, MD - VA San Diego Healthcare Syst
Objectives:
Upon completion of this activity, participants will be able to: (1) Explain how incretin-based therapies can ameliorate the pathophysiology of type 2 diabetes; (2) Compare and contrast incretin-based therapies with respoect to pharmacokinetics/pharmadynamics, efficacy, and saftey/side effects profile; (3) Discuss the use of incretin-based therapies in the treating of patients with type 2 diabetes considering therapeutic outcome, safety, tolerability, and potential for overcoming patient-related componenets of clincial inertia; (4) Recognize emerging therapies for type 2 diabetes and their stage of clinical development; and (5) State the scientific reationale behind these emerging therapies for type 2 diabetes.
Program Overview: 6:00 - 6:30 AM Registration & Meal Service
6:30 - 6:45 AM Case Study Introductions and Baseline Knowledge Assessment Robert R. Henry, MD - VA San Diego Healthcare Syst
6:45 - 7:05 AM Incretin-Based Therapies: Recent Clinical Evidence Lawrence Blonde, MD - Ochsner Clin Foundation
7:05 - 7:25 AM Incretin-Based Therapies: Applying Evidence and Guidelines in Practice
Derek Le Roith, MD, PhD - Mount Sinai Sch of Med
7:25 - 7:45 AM Emerging Strategies
Jaime A. Davidson, MD - Endocrine and Diabetes Associates of Texas
Wednesday, June 10, 2009 | 6:30 – 10:00 PM
Tuesday, June 9, 2009 
